Amylyx Pharmaceuticals Announces Interim Data From Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram Syndrome

CAMBRIDGE, Mass.--(BUSINESS WIRE) April 10, 2024 -- Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the“Company”) today announced interim data from the ongoing Phase 2 HELIOS clinical trial of AMX0035 (sodium...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials